MAPT and Alzheimer disease: As discussed above, lower iPLA2 activity has been observed in AD brains and considering our hypothesis that iPLA2γ is an important factor controlling AMPA-mediated toxicity in the hippocampus, we anticipated that defect in iPLA2γ activity can contribute to enhance Tau phosphorylation.